文献速递神经肿瘤

脑肿瘤类器官:用于脑肿瘤治疗预测与药物开发的快速、可重复且易用的个体化模型

Brain tumoroids: Treatment prediction and drug development for brain tumors with fast, reproducible, and easy-to-use personalized models.
PubMed 文献 · Neuro Oncol · 2025-01-01

研究纳入89例患者(81例原发肿瘤含77例胶质瘤,8例脑转移)构建肿瘤类器官,中位生成时间5天,成功率65%,在高别胶质瘤和脑转移中高于IDH突变低级别胶质瘤;类器官组织学与分子特征与亲本肿瘤相似,并能反映患者对放化疗和免疫治疗的应答。

要点

  • 肿瘤类器官中位生成时间5天,总成功率65%,高别胶质瘤和脑转移高于IDH突变低级别胶质瘤。
  • 类器官组织学(n=21)和分子特征(n=7)与亲本肿瘤相似,细胞组织随时间保持稳定。
  • 类器官与患者对放化疗的应答相关,并可借助可重复的3D分析流程评估免疫治疗应答。

核心结论

  • 患者来源肿瘤类器官模型稳健、易用、低成本且可重复,适用于所有原发或转移性脑肿瘤的治疗开发,可整合进未来早期临床试验。

研究设计与样本

  • 研究纳入89例患者,其中81例原发肿瘤包括77例胶质瘤,8例脑转移,构建肿瘤类器官并与亲本肿瘤比较。

主要发现

  • 所有分析的类器官组织学(n=21)和分子特征(n=7)与亲本肿瘤相似。
  • 类器官中位生成时间为5天,成功率为65%,高别胶质瘤和脑转移的成功率高于IDH突变低级别胶质瘤。
  • 在高别胶质瘤中,其他临床、神经影像、组织学或分子因素均不能预测类器官生成成功。
  • MACSima分析显示类器官内部细胞组织形成特定细胞亚群区域。
  • 类器官与患者对放化疗的应答相关,并能通过专用且可重复的3D分析流程响应免疫治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The generation of patient avatars is critically needed in neuro-oncology for treatment prediction and preclinical therapeutic development. Our objective was to develop a fast, reproducible, low-cost, and easy-to-use method of tumoroids generation and analysis, efficient for all types of brain tumors, primary and metastatic. METHODS: Tumoroids were generated from 89 patients: 81 primary tumors including 77 gliomas, and 8 brain metastases. Tumoroids morphology and cellular and molecular characteristics were compared with the ones of the parental tumor by using histology, methylome profiling, pTERT mutations, and multiplexed spatial immunofluorescences. Their cellular stability over time was validated by flow cytometry. Therapeutic sensitivity was evaluated and predictive factors of tumoroid generation were analyzed. RESULTS: All the tumoroids analyzed had similar histological (n = 21) and molecular features (n = 7) to the parental tumor. The median generation time was 5 days. The success rate was 65 %: it was higher for high-grade gliomas and brain metastases versus IDH mutated low-grade gliomas. For high-grade gliomas, neither other clinical, neuro-imaging, histological nor molecular factors were predictive of tumoroid generation success. The cellular organization inside tumoroids analyzed by MACSima revealed territories dedicated to specific cell subtypes. Finally, we showed the correlation between tumoroid and patient treatment responses to radio-chemotherapy and their ability to respond to immunotherapy thanks to a dedicated and reproducible 3D analysis workflow. CONCLUSIONS: Patient-derived tumoroid model that we developed offers a robust, user-friendly, low-cost, and reproducible preclinical model valuable for therapeutic development of all types of primary or metastatic brain tumors, allowing their integration into forthcoming early-phase clinical trials.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Soubéran A, Jiguet-Jiglaire C, Toutain S, et al. Brain tumoroids: Treatment prediction and drug development for brain tumors with fast, reproducible, and easy-to-use personalized models. Neuro Oncol. 2025. PMID: 39252580. doi:10.1093/neuonc/noae184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。